Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Morbid Obesity
Interventions: Laparoscopic Truncal Vagotomy; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 25 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: San Francisco, California • Rochester, New York

Conditions: Advanced/ Metastatic Renal Cell Cancer
Interventions: TKI258; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: San Francisco, California • Durham, North Carolina • Seattle, Washington

Conditions: Carcinoma, Hepatocellular
Interventions: pazopanib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute Pain, Post Operative Pain, Pain
Interventions: MR-107A-02, Tramadol, Placebo, Bunionectomy; Drug · Procedure
Lead sponsor: Viatris Specialty LLC; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 15
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 12 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: CYAD-02, ENDOXAN, Fludara; Biological · Drug
Lead sponsor: Celyad Oncology SA; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2035
U.S. locations: 2
States / cities: Jacksonville, Florida • Fairway, Kansas

Conditions: Primary Axillary Hyperhidrosis
Interventions: Ulthera System, Sham treatment; Device
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Roseville, California • Aventura, Florida • Chicago, Illinois + 3 more

Conditions: Bardet-Biedl Syndrome, POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity
Interventions: Setmelanotide; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Aurora, Colorado • New York, New York • Marshfield, Wisconsin

Conditions: Burns, Wound Healing
Interventions: Mepitel Ag; Device
Lead sponsor: Molnlycke Health Care AB; Industry
Eligibility: 2 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Phoenix, Arizona • Orlando, Florida • Indianapolis, Indiana + 3 more

Conditions: Glabellar Furrowing
Interventions: GFX; Device
Lead sponsor: Advanced Cosmetic Intervention; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: Beverly Hills, California • San Mateo, California • Tampa, Florida + 6 more

Conditions: Metastatic Colorectal Cancer
Interventions: Futuximab/modotuximab, Trifluridine/Tipiracil; Biological · Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Cleveland, Ohio

Conditions: Community-acquired Bacterial Pneumonia
Interventions: Solithromycin, Standard of Care; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 2 Months to 17 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more

Conditions: Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD)
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease
Interventions: Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin; Drug
Lead sponsor: Baim Institute for Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 25,682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 178
States / cities: Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more

Conditions: Asthma
Interventions: Placebo, GSK2190915; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • Oklahoma City, Oklahoma + 3 more

Conditions: COVID-19
Interventions: nirmatrelvir, ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 50
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 32 more

Conditions: Multiple System Atrophy
Interventions: ATH434; Drug
Lead sponsor: Alterity Therapeutics; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Aphakia, Cataract
Interventions: Light Adjustable lens (LAL) and Light Delivery Device (LDD), Control IOL; Device
Lead sponsor: RxSight, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Leawood, Kansas • Brecksville, Ohio • Sioux Falls, South Dakota + 3 more

Conditions: Multiple Myeloma
Interventions: PDR001, CJM112, LCL161; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Phoenix, Arizona • Nashville, Tennessee

Conditions: Colitis, Ulcerative
Interventions: Hyperbaric Oxygen Therapy; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: La Jolla, California • San Diego, California • Baltimore, Maryland + 5 more

Conditions: Plague
Interventions: Alhydrogel, rF1 and rV protein antigens; Biological
Lead sponsor: PharmAthene UK Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 9
States / cities: Huntsville, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 6 more

Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Interventions: Not listed
Lead sponsor: Adela, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more

Conditions: Osteoarthritis
Interventions: Total knee arthroplasty; Procedure
Lead sponsor: Exactech; Industry
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Neuralgia, Shingles, Peripheral Nervous System Disease
Interventions: REN-1654; Drug
Lead sponsor: Renovis; Industry
Eligibility: 55 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 16
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 12 more

Conditions: Brain and Central Nervous System Tumors
Interventions: bevacizumab; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Chicago, Illinois

Search by objective public record fields.

Safety and Efficacy of Laparoscopic Truncal Vagotomy for the Treatment of Obesity

A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer

A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis

Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

A Clinical Investigation to Evaluate Efficacy of Mepitel Ag in Partial Thickness Second Degree Burns

A Multi-center Long Term Efficacy Trial of the GFX For Reduction of Glabellar Furrowing

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

The Dual Antiplatelet Therapy Study (DAPT Study)

A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

A Biomarker Study of ATH434 in Participants With MSA

Clinical Study to Evaluate the Safety and Effectiveness of the RxSight Light Adjustable Lens (LAL) in Subjects With Prior Corneal Refractive Surgery

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares

One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Standard Total Knee Arthroplasty Using Platelet Rich Plasma (PRP)

Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

Bevacizumab in Treating Patients With Recurrent or Progressive Glioma